Matthew R Trendowski1, Jessica L Baedke2, Yadav Sapkota2, Lois B Travis3,4, Xindi Zhang1, Omar El Charif1, Heather E Wheeler5,6, Wendy M Leisenring7,8, Leslie L Robison2, Melissa M Hudson2,9, Lindsay M Morton10, Kevin C Oeffinger11, Rebecca M Howell12, Gregory T Armstrong2, Smita Bhatia13, M Eileen Dolan1. 1. Department of Medicine, University of Chicago, Chicago, Illinois. 2. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Medical Oncology, Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana. 4. Department of Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana. 5. Department of Biology, Loyola University Chicago, Chicago, Illinois. 6. Department of Computer Science, Loyola University Chicago, Chicago, Illinois. 7. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. 8. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 9. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 10. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 11. Department of Medicine, Duke University, Durham, North Carolina. 12. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 13. School of Medicine Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
BACKGROUND: Cranial radiation therapy (CRT) is associated with ototoxicity, which manifests as hearing loss and tinnitus. The authors sought to identify clinical determinants and genetic risk factors for ototoxicity among adult survivors of pediatric cancer treated with CRT. METHODS: Logistic regression evaluated associations of tinnitus (n = 1991) and hearing loss (n = 2198) with nongenetic risk factors and comorbidities among CRT-treated survivors in the Childhood Cancer Survivor Study. Genome-wide association studies (GWASs) of CRT-related tinnitus and hearing loss were also performed. RESULTS: Males were more likely to report CRT-related tinnitus (9.4% vs 5.4%; P = 5.1 × 10-4 ) and hearing loss (14.0% vs 10.7%; P = .02) than females. Survivors with tinnitus or hearing loss were more likely to experience persistent dizziness or vertigo (tinnitus: P < 2 × 10-16 ; hearing loss: P = 6.4 × 10-9 ), take antidepressants (tinnitus: P = .02; hearing loss: P = .01), and report poorer overall health (tinnitus: P = 1.5 × 10-6 ; hearing loss: P = 1.7 × 10-6 ) in comparison with controls. GWAS of CRT-related tinnitus revealed a genome-wide significant signal in chromosome 1 led by rs203248 (P = 1.5 × 10-9 ), whereas GWAS of CRT-related hearing loss identified rs332013 (P = 5.8 × 10-7 ) in chromosome 8 and rs67522722 (P = 7.8 × 10-7 ) in chromosome 6 as nearly genome-wide significant. A replication analysis identified rs67522722, intronic to ATXN1, as being significantly associated with CRT-related hearing loss (P = .03) and de novo hearing loss (P = 3.6 × 10-4 ). CONCLUSIONS: CRT-associated ototoxicity was associated with sex, several neuro-otological symptoms, increased antidepressant use, and poorer self-reported health. GWAS of CRT-related hearing loss identified rs67522722, which was supported in an independent cohort of survivors. LAY SUMMARY: Hearing loss and subjective tinnitus (the perception of noise or ringing in the ear) are long-term side effects of cancer treatment and are common in children treated with radiation to the brain. These toxicities can affect childhood development and potentially contribute to serious learning and behavioral difficulties. This study's data indicate that males are at greater risk for hearing loss and tinnitus than females after radiation therapy to the brain. Those who develop these toxicities are more likely to use antidepressants and report poorer overall health. Health care providers can improve the management of survivors by informing patients and/or their parents of these risks.
BACKGROUND: Cranial radiation therapy (CRT) is associated with ototoxicity, which manifests as hearing loss and tinnitus. The authors sought to identify clinical determinants and genetic risk factors for ototoxicity among adult survivors of pediatric cancer treated with CRT. METHODS: Logistic regression evaluated associations of tinnitus (n = 1991) and hearing loss (n = 2198) with nongenetic risk factors and comorbidities among CRT-treated survivors in the Childhood Cancer Survivor Study. Genome-wide association studies (GWASs) of CRT-related tinnitus and hearing loss were also performed. RESULTS: Males were more likely to report CRT-related tinnitus (9.4% vs 5.4%; P = 5.1 × 10-4 ) and hearing loss (14.0% vs 10.7%; P = .02) than females. Survivors with tinnitus or hearing loss were more likely to experience persistent dizziness or vertigo (tinnitus: P < 2 × 10-16 ; hearing loss: P = 6.4 × 10-9 ), take antidepressants (tinnitus: P = .02; hearing loss: P = .01), and report poorer overall health (tinnitus: P = 1.5 × 10-6 ; hearing loss: P = 1.7 × 10-6 ) in comparison with controls. GWAS of CRT-related tinnitus revealed a genome-wide significant signal in chromosome 1 led by rs203248 (P = 1.5 × 10-9 ), whereas GWAS of CRT-related hearing loss identified rs332013 (P = 5.8 × 10-7 ) in chromosome 8 and rs67522722 (P = 7.8 × 10-7 ) in chromosome 6 as nearly genome-wide significant. A replication analysis identified rs67522722, intronic to ATXN1, as being significantly associated with CRT-related hearing loss (P = .03) and de novo hearing loss (P = 3.6 × 10-4 ). CONCLUSIONS: CRT-associated ototoxicity was associated with sex, several neuro-otological symptoms, increased antidepressant use, and poorer self-reported health. GWAS of CRT-related hearing loss identified rs67522722, which was supported in an independent cohort of survivors. LAY SUMMARY: Hearing loss and subjective tinnitus (the perception of noise or ringing in the ear) are long-term side effects of cancer treatment and are common in children treated with radiation to the brain. These toxicities can affect childhood development and potentially contribute to serious learning and behavioral difficulties. This study's data indicate that males are at greater risk for hearing loss and tinnitus than females after radiation therapy to the brain. Those who develop these toxicities are more likely to use antidepressants and report poorer overall health. Health care providers can improve the management of survivors by informing patients and/or their parents of these risks.
Authors: Annelot J M Meijer; Eva Clemens; Alex E Hoetink; Martine van Grotel; Marry M van den Heuvel-Eibrink Journal: Crit Rev Oncol Hematol Date: 2019-01-11 Impact factor: 6.312
Authors: Thorsten Langer; Eva Clemens; Linda Broer; Lara Maier; André G Uitterlinden; Andrica C H de Vries; Martine van Grotel; Saskia F M Pluijm; Harald Binder; Benjamin Mayer; Annika von dem Knesebeck; Julianne Byrne; Eline van Dulmen-den Broeder; Marco Crocco; Desiree Grabow; Peter Kaatsch; Melanie Kaiser; Claudia Spix; Line Kenborg; Jeanette F Winther; Catherine Rechnitzer; Henrik Hasle; Tomas Kepak; Anne-Lotte F van der Kooi; Leontien C Kremer; Jarmila Kruseova; Stefan Bielack; Benjamin Sorg; Stefanie Hecker-Nolting; Claudia E Kuehni; Marc Ansari; Martin Kompis; Heleen van der Pal; Ross Parfitt; Dirk Deuster; Peter Matulat; Amelie Tillmanns; Wim J E Tissing; Jörn D Beck; Susanne Elsner; Antoinette Am Zehnhoff-Dinnesen; Marry M van den Heuvel-Eibrink; Oliver Zolk Journal: Eur J Cancer Date: 2020-09-06 Impact factor: 9.162
Authors: Judit M Pérez Ortiz; Nissa Mollema; Nicholas Toker; Carolyn J Adamski; Brennon O'Callaghan; Lisa Duvick; Jillian Friedrich; Michael A Walters; Jessica Strasser; Jon E Hawkinson; Huda Y Zoghbi; Christine Henzler; Harry T Orr; Sarita Lagalwar Journal: Neurobiol Dis Date: 2018-05-11 Impact factor: 5.996
Authors: Tara M Brinkman; Johnnie K Bass; Zhenghong Li; Kirsten K Ness; Amar Gajjar; Alberto S Pappo; Gregory T Armstrong; Thomas E Merchant; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: Cancer Date: 2015-08-19 Impact factor: 6.860
Authors: Lindsay M Morton; Joshua N Sampson; Gregory T Armstrong; Ting-Huei Chen; Melissa M Hudson; Eric Karlins; Casey L Dagnall; Shengchao Alfred Li; Carmen L Wilson; Deo Kumar Srivastava; Wei Liu; Guolian Kang; Kevin C Oeffinger; Tara O Henderson; Chaya S Moskowitz; Todd M Gibson; Diana M Merino; Jeannette R Wong; Sue Hammond; Joseph P Neglia; Lucie M Turcotte; Jeremy Miller; Laura Bowen; William A Wheeler; Wendy M Leisenring; John A Whitton; Laurie Burdette; Charles Chung; Belynda D Hicks; Kristine Jones; Mitchell J Machiela; Aurelie Vogt; Zhaoming Wang; Meredith Yeager; Geoffrey Neale; Matthew Lear; Louise C Strong; Yutaka Yasui; Marilyn Stovall; Rita E Weathers; Susan A Smith; Rebecca Howell; Stella M Davies; Gretchen A Radloff; Kenan Onel; Amy Berrington de González; Peter D Inskip; Preetha Rajaraman; Joseph F Fraumeni; Smita Bhatia; Stephen J Chanock; Margaret A Tucker; Leslie L Robison Journal: J Natl Cancer Inst Date: 2017-11-01 Impact factor: 13.506
Authors: Gregory T Armstrong; Yan Chen; Yutaka Yasui; Wendy Leisenring; Todd M Gibson; Ann C Mertens; Marilyn Stovall; Kevin C Oeffinger; Smita Bhatia; Kevin R Krull; Paul C Nathan; Joseph P Neglia; Daniel M Green; Melissa M Hudson; Leslie L Robison Journal: N Engl J Med Date: 2016-01-13 Impact factor: 91.245
Authors: Elizabeth M Wells; Nicole J Ullrich; Kristy Seidel; Wendy Leisenring; Charles A Sklar; Gregory T Armstrong; Lisa Diller; Allison King; Kevin R Krull; Joseph P Neglia; Marilyn Stovall; Kimberly Whelan; Kevin C Oeffinger; Leslie L Robison; Roger J Packer Journal: Neuro Oncol Date: 2018-01-10 Impact factor: 12.300
Authors: Yuliang Wang; Anthony Pak Yin Liu; Tatia Mei-Chun Lee; Wilfred Hing Sang Wong; Daniel Yee Tak Fong; Lok Kan Leung; Matthew Ming Kong Shing; Dennis Tak-Loi Ku; Godfrey Chi-Fung Chan; Winnie Wan-Yee Tso Journal: Cancers (Basel) Date: 2022-07-04 Impact factor: 6.575